de Lemos Mário L, Badry Nadine, Kletas Victoria, Fabbro Joan, Tew Amber
1 Provincial Pharmacy, Systemic Therapy Program, BC Cancer Agency, Vancouver, BC, Canada.
2 Provincial Pharmacy Systemic Therapy Program, BC Cancer Agency, Victoria, BC, Canada.
J Oncol Pharm Pract. 2018 Apr;24(3):218-220. doi: 10.1177/1078155217698846. Epub 2017 Mar 16.
It has been argued that the larger molecular weight of hazardous monoclonal antibodies may prevent their dermal absorption via occupational exposure. However, this assertion does not seem to be supported by direct evidence. Although the larger molecular weight may render monoclonal antibodies less probable to achieve therapeutic systemic level through dermal absorption, the concern in occupational health is whether these drugs can possibly attain a detectable level through repeated dermal exposure. Currently, there is no direct evidence to support a particular molecular weight above which a drug cannot achieve a detectable level following repeated occupational exposure. Therefore, the precautionary principle would dictate that repeated exposure of healthcare workers to hazardous monoclonal antibodies should be kept to a minimum.
有人认为，危险单克隆抗体较大的分子量可能会阻止其通过职业暴露经皮肤吸收。然而，这一说法似乎没有直接证据支持。虽然较大的分子量可能使单克隆抗体通过皮肤吸收达到治疗性全身水平的可能性降低，但职业健康方面关注的是，这些药物通过反复皮肤接触是否可能达到可检测水平。目前，没有直接证据支持存在一个特定的分子量，超过该分子量后药物在反复职业暴露后无法达到可检测水平。因此，预防原则要求医护人员对危险单克隆抗体的反复接触应降至最低。
